COVID19 and its impact on clinical cancer research: the EORTC network experience
30 Jun 2020
The impact to innovation and the affect to cancer patients will be measured in the coming years. In the last month, with the reduction of number of new COVID-19 cases easing the stress on country wide healthcare systems has meant that the EORTC network can resume their research activities and start recruiting patients again. The research community is bracing itself for the financial crisis following the aftermath of the pandemic, as this will determine the funding that will be available to conduct clinical research especially for independent trials. A recent survey completed by the EORTC network has demonstrated that the response of hospitals in general in the EU (but not the case in UK) has been to maintain clinical cancer research activities as much as possible. After an expected decrease of recruitment on clinical trials, it can be seen that specific exit strategies are at various stages of maturity, showing a revitalized increase in the recruitment of patients to clinical trials.
“EORTC is grateful to its network and its key representatives across Europe for their continued support despite the new challenges they had to face,” said Dr Denis Lacombe, EORTC Director General. “We continue with our mission to improve survival and quality of life of patients. This pandemic can only make us more determined to provide the best innovation in treatment and care for cancer patients.”
Reference
1Safeguarding cancer care in a post-COVID-19 world
Editorial; The Lancet Oncology; volume 21, issue 5, p603, May 01, 2020; DOI: https://doi.org/10.1016/S1470-2045(20)30243-6
2Effect of the COVID-19 pandemic on cancer treatment and research
Lancet Haematol 2020; Comment; Vol 7, Issue 6, E423-E435; April 24, 2020; https://doi.org/10.1016/S2352-3026(20)30123-X
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023